Ascentage Pharma releases latest results from multiple clinical studies of lead drug candidates
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Establishing Asymchem’s first manufacturing footprint in Europe
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Subscribe To Our Newsletter & Stay Updated